Current Studies

Infant Vaccine Study

Find out more about this study

Please fill out the form below and we will be in touch shortly.

Participants needed: Two month old infants

About pneumococcal disease

  • Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae.
  • This bacteria can cause very severe infections such as bacteremia (blood poisoning), meningitis (brain infection) and pneumonia, and less severe infections like ear and sinus infections.
  • Without vaccination, children under two years of age have the highest rates of disease.

What is the purpose of this study?

  • The purpose of the study is to find out if two doses of pneumococcal vaccine (PCV) – Prevnar13®is as good as three doses (which is currently used in NS and most other provinces/territories in Canada) in protecting children against pneumococcal disease.
  • We would like to find out if it is possible to achieve the same protection against pneumococcal infection using just two injections, at two and 12 months.
  • This would reduce the number of needles needed for infants in the future, and result in significant cost savings across Canada.

Is my child eligible to participate?

  • We are in need of healthy, two-month old infants.

Participant Commitment

  • The study involves six visits over an 11-month period.
  • Your child is seen at CCfV when your child is 2, 4, 5, 6, 12, and 13 months old.
  • Visits will include three blood tests (total), routine vaccinations, physical exams, and questions about your baby’s health.

You will receive:

  • Reimbursement for your out of pocket expenses related to the study such as travel and parking.
  • Study staff will be giving all routine infant vaccinations up to 12 months of age.
  • We will send documentation to you and to Public Health and record these vaccines on the child’s vaccination record.

Contact Pamela MacIntyre

Phone (902) 470-8948

Email Pamela.MacIntyre@iwk.nshealth.ca

Find out more about this study

Please fill out the form below and we will be in touch shortly.